Sumitomo Mitsui DS Asset Management Company Ltd Purchases 5,385 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Sumitomo Mitsui DS Asset Management Company Ltd raised its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 38.9% during the third quarter, Holdings Channel reports. The firm owned 19,220 shares of the biopharmaceutical company’s stock after purchasing an additional 5,385 shares during the period. Sumitomo Mitsui DS Asset Management Company Ltd’s holdings in Regeneron Pharmaceuticals were worth $20,205,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Fisher Asset Management LLC grew its holdings in Regeneron Pharmaceuticals by 9.2% during the 4th quarter. Fisher Asset Management LLC now owns 5,622 shares of the biopharmaceutical company’s stock worth $4,938,000 after acquiring an additional 472 shares during the period. B. Riley Wealth Advisors Inc. grew its holdings in Regeneron Pharmaceuticals by 15.7% in the fourth quarter. B. Riley Wealth Advisors Inc. now owns 1,164 shares of the biopharmaceutical company’s stock worth $1,022,000 after purchasing an additional 158 shares during the period. Wedmont Private Capital increased its stake in Regeneron Pharmaceuticals by 19.6% in the first quarter. Wedmont Private Capital now owns 1,423 shares of the biopharmaceutical company’s stock valued at $1,343,000 after purchasing an additional 233 shares in the last quarter. Park Avenue Securities LLC raised its holdings in shares of Regeneron Pharmaceuticals by 9.2% during the first quarter. Park Avenue Securities LLC now owns 1,671 shares of the biopharmaceutical company’s stock valued at $1,609,000 after purchasing an additional 141 shares during the period. Finally, Gulf International Bank UK Ltd increased its position in Regeneron Pharmaceuticals by 0.5% in the 1st quarter. Gulf International Bank UK Ltd now owns 8,907 shares of the biopharmaceutical company’s stock valued at $8,572,000 after buying an additional 43 shares in the last quarter. 83.31% of the stock is owned by institutional investors.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other news, CFO Christopher R. Fenimore sold 5,680 shares of the business’s stock in a transaction on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the completion of the transaction, the chief financial officer now directly owns 15,305 shares in the company, valued at $18,447,575.65. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other Regeneron Pharmaceuticals news, CFO Christopher R. Fenimore sold 5,680 shares of the firm’s stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the sale, the chief financial officer now owns 15,305 shares of the company’s stock, valued at $18,447,575.65. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, VP Jason Pitofsky sold 487 shares of the business’s stock in a transaction dated Wednesday, August 7th. The stock was sold at an average price of $1,070.00, for a total value of $521,090.00. Following the transaction, the vice president now directly owns 4,204 shares of the company’s stock, valued at $4,498,280. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders own 7.48% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

NASDAQ REGN opened at $998.23 on Friday. The company has a quick ratio of 4.62, a current ratio of 5.44 and a debt-to-equity ratio of 0.10. The company has a market cap of $110.04 billion, a PE ratio of 26.44, a price-to-earnings-growth ratio of 3.45 and a beta of 0.12. Regeneron Pharmaceuticals, Inc. has a 52 week low of $769.19 and a 52 week high of $1,211.20. The firm’s 50-day simple moving average is $1,112.39 and its two-hundred day simple moving average is $1,039.64.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share for the quarter, beating analysts’ consensus estimates of $8.93 by $2.63. The business had revenue of $3.55 billion during the quarter, compared to analyst estimates of $3.38 billion. Regeneron Pharmaceuticals had a net margin of 32.04% and a return on equity of 16.80%. Regeneron Pharmaceuticals’s revenue was up 12.3% compared to the same quarter last year. During the same period in the previous year, the business earned $8.79 EPS. Research analysts predict that Regeneron Pharmaceuticals, Inc. will post 37.85 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on REGN. Canaccord Genuity Group reiterated a “buy” rating and set a $1,152.00 price objective on shares of Regeneron Pharmaceuticals in a report on Thursday, June 27th. Guggenheim lifted their price target on Regeneron Pharmaceuticals from $1,180.00 to $1,300.00 and gave the company a “buy” rating in a research note on Friday, August 2nd. Argus increased their price objective on Regeneron Pharmaceuticals from $1,060.00 to $1,170.00 and gave the stock a “buy” rating in a research note on Tuesday, June 25th. Leerink Partnrs lowered Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 24th. Finally, Piper Sandler upped their price target on Regeneron Pharmaceuticals from $1,166.00 to $1,242.00 and gave the stock an “overweight” rating in a report on Friday, August 23rd. One analyst has rated the stock with a sell rating, four have given a hold rating, sixteen have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $1,116.00.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.